LEXICON PHARMACEUTICALS, INC. Available-for-sale Securities
LEXICON PHARMACEUTICALS, INC. (LXRX) had Available-for-sale Securities of $92.01 million as of 2022-12-31, per its 10-Q filed 2023-05-04.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecurities · last filed 2023-05-04
- 2022-12-31: Available-for-sale Securities $92.01M.
- 2022-03-31: Available-for-sale Securities $26.98M.
- 2021-12-31: Available-for-sale Securities $22.68M.
- 2021-09-30: Available-for-sale Securities $28.80M.
| Period end | Available-for-sale Securities |
|---|---|
| 2022-12-31 | $92.01M 10-Q · filed 2023-05-04 |
| 2022-03-31 | $26.98M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $22.68M 10-K · filed 2023-03-03 |
| 2021-09-30 | $28.80M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $28.61M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $43.71M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $26.01M 10-K · filed 2022-03-10 |
| 2020-09-30 | $59.20M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $114.92M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $193.54M 10-Q · filed 2020-04-27 |
| 2019-12-31 | $235.55M 10-K · filed 2021-03-12 |
| 2019-09-30 | $126.10M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $94.87M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $87.37M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $79.67M 10-K · filed 2020-03-12 |
| 2018-09-30 | $138.40M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $194.65M 10-Q · filed 2018-07-30 |
| 2018-03-31 | $241.85M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $249.13M 10-K · filed 2019-03-15 |
| 2017-09-30 | $113.52M 10-Q · filed 2017-11-08 |
| 2016-12-31 | $299.90M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |